The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer
Open Access
- 31 August 2004
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (7) , 1236-1238
- https://doi.org/10.1038/sj.bjc.6602152
Abstract
The prognostic value of C-reactive protein, compared with ECOG performance status (ECOG-ps), in patients receiving alpha-interferon treatment for advanced renal cancer was assessed in 58 patients. In all, 55 patients died on follow-up. On multivariate analysis with ECOG-ps and C-reactive protein entered as covariates, only C-reactive protein was a significant independent predictor of survival (HR 2.03, 95% CI 1.09–3.80, P=0.026).Keywords
This publication has 17 references indexed in Scilit:
- Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancerBritish Journal of Cancer, 2004
- Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancerBritish Journal of Cancer, 2003
- Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapyThe Lancet Oncology, 2003
- Systemic inflammatory response predicts survival following curative resection of colorectal cancerBritish Journal of Surgery, 2003
- The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancerBritish Journal of Cancer, 2002
- Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase responseBritish Journal of Cancer, 2002
- The role of C-reactive protein as a prognostic indicator in advanced cancerCurrent Oncology Reports, 2002
- Prognostic Factors in Advanced Gastrointestinal Cancer Patients With Weight LossNutrition and Cancer, 2000
- Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trialThe Lancet, 1999
- Serum acute phase reactants and prognosis in renal cell carcinomaCancer, 1995